Journal of Vaccine Research 2024, Vol.14, No.2, 65-75 http://medscipublisher.com/index.php/jvr 65 Research Report Open Access The Role of Adjuvants in Cancer Vaccine Development Jianmin Liu Sinovac Biotech Co., Ltd., Haiding, 100193, Beijing, China Corresponding email: Jianminliu@sinovac.com Journal of Vaccine Research, 2024, Vol.14, No.2 doi: 10.5376/jvr.2024.14.0008 Received: 18 Mar., 2024 Accepted: 22 Apr., 2024 Published: 03 May, 2024 Copyright © 2024 Liu, This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Preferred citation for this article: Liu J.M., 2024, The role of adjuvants in cancer vaccine development, Journal of Vaccine Research, 14(2): 65-75 (doi: 10.5376/jvr.2024.14.0008) Abstract The study highlights several key findings regarding the use of adjuvants in cancer vaccines. Adjuvants such as Toll-like receptor agonists, saponins, and cytokines have been shown to significantly enhance the immune response by promoting antigen presentation and stimulating both innate and adaptive immunity. Novel adjuvants like QS-21 have demonstrated the ability to activate the NLRP3 inflammasome, leading to the release of cytokines crucial for Th1 responses, thereby improving vaccine efficacy. Additionally, combinatorial adjuvant strategies that target multiple branches of the immune response have been found to overcome obstacles related to antigen immunogenicity and tumor immune suppression. The use of adjuvants in conjunction with other treatments such as chemotherapy and radiotherapy has also been shown to enhance the overall immune response in a compromised environment. The findings underscore the critical role of adjuvants in the development of effective cancer vaccines. By enhancing antigen presentation and stimulating robust immune responses, adjuvants can significantly improve the efficacy of cancer vaccines. Future research should focus on optimizing adjuvant formulations and exploring novel adjuvant combinations to further enhance the therapeutic potential of cancer vaccines. Keywords Cancer vaccines; Adjuvants; Immunogenicity; Immune response; Tumor antigens; QS-21, Toll-like receptor agonists; Combinatorial adjuvant strategies 1 Introduction Cancer vaccines have emerged as a promising therapeutic strategy aimed at harnessing the body's immune system to target and eliminate cancer cells. Unlike traditional vaccines that prevent infectious diseases, cancer vaccines are designed to treat existing malignancies by stimulating an immune response against tumor-specific antigens. Over the past few decades, significant progress has been made in the development of therapeutic cancer vaccines, with various approaches being explored to enhance their efficacy (Bowen et al., 2018; Alarcon et al., 2022). Despite these advancements, the clinical success of cancer vaccines has been limited, primarily due to challenges such as poor immunogenicity of tumor antigens and the immunosuppressive tumor microenvironment (Vermaelen, 2019). Adjuvants play a crucial role in the effectiveness of cancer vaccines. They are substances that enhance the body's immune response to an antigen, making the vaccine more effective. In the context of cancer vaccines, adjuvants are essential for overcoming the inherent challenges posed by the tumor microenvironment, such as immune evasion and suppression (Bowen et al., 2018; Vermaelen, 2019). Recent research has focused on developing novel adjuvants and combinatorial adjuvant strategies that can target multiple branches of the immune response, thereby improving the immunogenicity of tumor antigens and counteracting tumor-induced immune suppression (Bowen et al., 2018; Puth et al., 2022). For instance, pattern recognition receptor (PRR)-targeting adjuvants and their delivery platforms have shown promise in enhancing the efficacy of cancer vaccines (Alarcon et al., 2022). This study explores the role of adjuvants in the development of effective cancer vaccines. By reviewing the current literature and recent advancements in adjuvant technology, this study aims to provide a comprehensive understanding of how adjuvants can be utilized to enhance the immune response against cancer. Specifically, the study will examine various classes of adjuvants, their mechanisms of action, and their potential to improve the clinical outcomes of cancer vaccine therapies. Through this investigation, we hope to identify key strategies that can be employed to overcome the existing challenges in cancer vaccine development and pave the way for more effective therapeutic interventions.
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==